Correlation Between Zentalis Pharmaceuticals and Theriva Biologics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Theriva Biologics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Theriva Biologics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Theriva Biologics, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Theriva Biologics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Theriva Biologics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Theriva Biologics.

Diversification Opportunities for Zentalis Pharmaceuticals and Theriva Biologics

0.42
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Zentalis and Theriva is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Theriva Biologics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Theriva Biologics and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Theriva Biologics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Theriva Biologics has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Theriva Biologics go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Theriva Biologics

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to generate 0.56 times more return on investment than Theriva Biologics. However, Zentalis Pharmaceuticals Llc is 1.8 times less risky than Theriva Biologics. It trades about -0.05 of its potential returns per unit of risk. Theriva Biologics is currently generating about -0.14 per unit of risk. If you would invest  416.00  in Zentalis Pharmaceuticals Llc on September 18, 2024 and sell it today you would lose (107.00) from holding Zentalis Pharmaceuticals Llc or give up 25.72% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Zentalis Pharmaceuticals Llc  vs.  Theriva Biologics

 Performance 
       Timeline  
Zentalis Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Theriva Biologics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Theriva Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Zentalis Pharmaceuticals and Theriva Biologics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zentalis Pharmaceuticals and Theriva Biologics

The main advantage of trading using opposite Zentalis Pharmaceuticals and Theriva Biologics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Theriva Biologics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Theriva Biologics will offset losses from the drop in Theriva Biologics' long position.
The idea behind Zentalis Pharmaceuticals Llc and Theriva Biologics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets